SI - LIRAGLUTIDE SOLUTION FOR INJECTION IN PRE-FILLED PEN 6MG/ML [SIN17618P]
Active ingredients: LIRAGLUTIDE
Product Info
SI - LIRAGLUTIDE SOLUTION FOR INJECTION IN PRE-FILLED PEN 6MG/ML
[SIN17618P]
Product information
Active Ingredient and Strength | LIRAGLUTIDE - 6 MG/ML |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | HYBIO PHARMACEUTICAL CO., LTD. (PINGSHAN FACTORY) - CHINA |
Registration Number | SIN17618P |
Licence Holder | SINO-INNOVAX BIOTEC PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | A10BJ02 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Therapeutic indications
SI - Liraglutide Solution for Injection in Pre-Filled Pen is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
in addition to other medicinal products for the treatment of diabetes (see Pharmacodynamic properties – Clinical efficacy and safety section – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Dosing
4.2 Posology and method of administration
Posology
Adults
To improve gastro-intestinal tolerability, the starting dose is 0.6 mg liraglutide daily. After at least one week, the dose should be increased to 1.2 mg. Some patients are expected to benefit from an increase in dose from 1.2 mg to 1.8 mg and based on clinical response, after at least one week, the dose can be increased to 1.8 mg to further improve glycaemic control. Daily doses higher than 1.8 mg are not recommended.
When liraglutide is added to a sulfonylurea or insulin, a reduction in the dose of sulfonylurea or insulin should be considered to reduce the risk of hypoglycaemia (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Combination therapy with sulfonylurea is only valid for adult patients.
Self-monitoring of blood glucose is not needed in order to adjust the dose of liraglutide. Blood glucose self-monitoring is necessary to adjust the dose of sulfonylurea and insulin, particularly when liraglutide therapy is started and insulin is reduced. A stepwise approach to insulin dose reduction is recommended.
No dose adjustment is required during Ramadan when liraglutide is added to metformin for treatment of type 2 diabetes mellitus (see Other clinical data – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). It is recommended to finalise dose escalation of liraglutide before patients start Ramadan fasting.
Children aged 10 years and above
To improve gastro-intestinal tolerability, the starting dose is 0.6 mg liraglutide daily. After at least one week, the dose may be increased to 1.2 mg daily if additional glycaemic control is required. The dose can be increased to 1.8 mg daily if required to further improve glycaemic control after at least one week of treatment with the 1.2 mg daily dose.
Special populations
Elderly patients (>65 years old): No dose adjustment is required based on age (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Renal impairment: No dose adjustment is required for patients with mild, moderate or severe renal impairment. There is no therapeutic experience in patients with end-stage renal disease and, liraglutide is therefore not recommended for use in these patients (see sections 5.1 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hepatic impairment: No dose adjustment is recommended for patients with mild or moderate hepatic impairment. Liraglutide is not recommended for use in patients with severe hepatic impairment (see section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Paediatric population: No data are available for children below 10 years of age (see sections 5.1 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Method of administration
Liraglutide must not be administered intravenously or intramuscularly.
Liraglutide is administered once daily at any time, independent of meals, and can be injected subcutaneously in the abdomen, in the thigh or in the upper arm. The injection site and timing can be changed without dose adjustment. However, it is preferable that liraglutide is injected around the same time of the day, when the most convenient time of the day has been chosen. Injection sites should always be rotated in order to reduce the risk of injection site amyloid deposits (see section and 4.8 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). For further instructions on administration (see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
